CorMedix Revenue Falls To $54.5 Million From $104.3 Million As DefenCath Pricing Drops
CorMedix suspended its 2027 DefenCath sales outlook while keeping its 2026 revenue forecast at $325 million to $345 million.
CorMedix, which sells DefenCath to prevent bloodstream infections in dialysis patients, reported Thursday that third-quarter revenue fell to $54.5 million from $104.3 million a year earlier, according to its SEC earnings filing. The company attributed the decline largely to lower DefenCath pricing in its earnings release, and suspended its 2027 revenue forecast for the drug.
DefenCath's price reset
DefenCath generated $17.2 million of revenue, including a $5.0 million benefit from revised estimates of sales allowances. Other products and grant income supplied $37.3 million of the unaudited quarterly total.
CorMedix said DefenCath's July 1, 2026 transition out of a temporary Medicare payment period reduced net pricing. Large outpatient dialysis customers largely maintained usage during the quarter, the company said.
DefenCath is a solution used in catheters to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis. It is CorMedix's biggest net-sales contributor, sold mainly to outpatient dialysis clinics and inpatient hospitals. The company believes its contracted dialysis customers cover roughly 60% of U.S. outpatient dialysis centers.
Changes to Medicare's reimbursement framework led management to suspend its previously issued 2027 DefenCath forecast. CorMedix expects to give guidance in early 2027, when it anticipates better visibility into customer pricing, usage and possible revenue from Medicare Advantage contracts.
Lower costs, much lower adjusted earnings
Adjusted EBITDA—a measure excluding interest, taxes and selected expenses—fell to $3.1 million from $71.9 million a year earlier. The current calculation also removes the $5.0 million sales-allowance benefit.
The quarterly net loss was $14.7 million, including $11.5 million of non-cash expense from revaluing payments tied to the Melinta acquisition. A year earlier, CorMedix earned $108.6 million, helped by a $59.7 million one-time tax benefit. Basic and diluted losses were both $0.19 per share, versus earnings of $1.42 and $1.26, respectively.
Operating expenses fell approximately 12% to $36.6 million from $41.7 million. Administrative spending declined approximately 30% to $17.9 million from $25.5 million, primarily because the earlier quarter included Melinta transaction and integration costs, CorMedix said.
Research spending rose to $7.0 million from $5.1 million, which management attributed mainly to personnel and clinical-trial services. Marketing spending increased approximately 4% to $11.7 million from $11.2 million, principally because of staffing and programs supporting the larger portfolio.
CorMedix retained its 2026 revenue forecast of $325 million to $345 million. It narrowed adjusted EBITDA guidance to $130 million to $140 million from $125 million to $140 million, and lowered expected cash operating expenses to $140 million to $145 million from $145 million to $155 million.
Building beyond the dialysis drug
CorMedix closed its Melinta purchase on August 29, 2025, adding six infectious-disease products, including REZZAYO, MINOCIN IV and VABOMERE, alongside the cardiovascular drug TOPROL-XL. Those operations contributed a full quarter of sales this year versus one month a year earlier, partially offsetting DefenCath's decline.
On Monday, CorMedix agreed to buy Heron's assets for $145 million upfront in cash plus 14,583,333 shares. The pending purchase adds four commercial products for postsurgical pain and nausea associated with surgery or chemotherapy, extending its hospital and infusion-center business.
CorMedix Chairman and CEO Joseph Todisco said, “we expect the Heron transaction to effectively double the Company’s non-DefenCath annual product revenue.” Management anticipates closing in the first quarter of 2027 and expects Heron revenue of $125 million to $150 million for full-year 2027.
CorMedix arranged a term loan of up to $150 million and expects to draw $75 million at closing. It held $355.2 million in cash and equivalents, excluding restricted cash, on September 30. Operating cash flow for the first nine months rose to $218.3 million from $80.6 million; management attributed the increase to higher year-to-date earnings and working-capital movements, including rebate-payment timing.
CorMedix anticipates an FDA decision in the first quarter of 2027 on REZZAYO's proposed use to prevent invasive fungal disease, an application accepted for priority review on October 19. If approved, the company plans to begin promotion in the second half of 2027.
Sources
- 8-K Filing — CorMedix Inc. (CRMD) — SEC EDGAR
- Exhibit crmd_q32026earningspr.htm — CorMedix Inc. 8-K exhibit — SEC EDGAR
- Cary public company sells nearly all assets in $222M deal - Triangle Business Journal — bizjournals.com
- Cormedix Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- CorMedix Therapeutics to Acquire Substantially All Assets — globenewswire.com
- Heron Therapeutics Announces Third Quarter 2026 Financial — globenewswire.com